https://bostonbiotechwatch.com/2017/11/23/lab-notebook-software-bypassed-by-biologists-poses-tough-challenge-for-software-developers/https://bostonbiotechwatch.com/wp-content/uploads/2017/11/lab-notebook-_sl1500_.jpgLab notebook _SL1500_2017-11-23T19:24:48+00:00monthlyhttps://bostonbiotechwatch.com/2017/04/14/can-this-181-billion-fund-you-have-never-heard-of-succeed-at-playing-the-long-game-in-life-sciences/https://bostonbiotechwatch.com/wp-content/uploads/2017/04/table.jpgTable 1Table 1. Baillie Gifford’s publicly disclosed life sciences and healthcare investments (not including health IT investment ZocDoc) as of April 11, 2017. Data from Pitchbook and Crunchbasehttps://bostonbiotechwatch.com/wp-content/uploads/2017/04/slater_tom_0229_color.jpgTom SlaterTom Slater. Photo courtesy Tom Slaterhttps://bostonbiotechwatch.com/wp-content/uploads/2017/04/edinburgh-castle-forbes-photo.jpgEdinburgh castle Forbes photo2017-04-15T02:28:24+00:00monthlyhttps://bostonbiotechwatch.com/2017/02/02/qa-bryan-roberts/https://bostonbiotechwatch.com/wp-content/uploads/2017/02/bryan_roberts.jpgbryan_robertshttps://bostonbiotechwatch.com/wp-content/uploads/2017/02/bryan_roberts-cropped.jpgbryan_roberts-cropped2017-02-02T13:10:31+00:00monthlyhttps://bostonbiotechwatch.com/2016/02/02/can-biology-even-drug-discovery-ever-be-clouded-its-early-but-andreesen-horowitz-vc-thinks-so/2016-02-02T16:49:47+00:00monthlyhttps://bostonbiotechwatch.com/2015/05/26/why-denali-raised-a-217-million-financing-round-not-just-because-it-could/2015-05-26T17:53:07+00:00monthlyhttps://bostonbiotechwatch.com/2015/03/25/can-pharma-conquer-the-consumer-the-way-apple-did-this-app-might-help/https://bostonbiotechwatch.com/wp-content/uploads/2015/03/simonmeier7-400-wide.jpgSimon MeierSimon Meier of Roche Venture Fund2015-03-25T19:40:29+00:00monthlyhttps://bostonbiotechwatch.com/2015/02/11/coming-to-an-app-store-near-you-drug-like-interventions/2015-02-11T19:11:14+00:00monthlyhttps://bostonbiotechwatch.com/2015/02/03/bio-ceo-2015-conference-preview/https://bostonbiotechwatch.com/wp-content/uploads/2015/02/bio-ceo2013_205x100_thumbnail.jpgBIO CEO2013_205x100_Thumbnail2015-02-03T17:18:06+00:00monthlyhttps://bostonbiotechwatch.com/2015/01/19/it-had-to-be-you-why-roche-was-the-lone-suitor-for-foundation-medicine/2015-01-19T14:13:30+00:00monthlyhttps://bostonbiotechwatch.com/2014/10/23/why-have-only-a-few-european-biotechs-made-it-through-the-ipo-window/https://bostonbiotechwatch.com/wp-content/uploads/2014/10/eu-ipo-table1.jpgEU IPO TablePerformance of some IPOs by European biotechs. Bold: CBT Advisors clientshttps://bostonbiotechwatch.com/wp-content/uploads/2014/10/eu-ipo-table.jpgEU IPO TableTable 1: Performance of some IPOs by European biotechs. Bold: CBT Advisors clienthttps://bostonbiotechwatch.com/wp-content/uploads/2014/10/biotech-deal-volumes.pngBiotech deal volumesFigure 1: Europe lags in volume. Data courtesy Dealogic. Figure courtesy FT.2014-12-29T13:49:06+00:00monthlyhttps://bostonbiotechwatch.com/2012/03/19/how-i-stopped-worrying-and-learned-to-love-twitter-top-hundred-life-sciences-twitterers-to-follow/2014-10-23T12:31:43+00:00monthlyhttps://bostonbiotechwatch.com/2014/10/15/sure-biotech-is-hot-but-are-biotech-ipos-a-good-investment/https://bostonbiotechwatch.com/wp-content/uploads/2014/10/graphs3a.jpgGraphs3ahttps://bostonbiotechwatch.com/wp-content/uploads/2014/10/graphs3.jpgGraphs3https://bostonbiotechwatch.com/wp-content/uploads/2014/10/graphs2.jpgGraphs2https://bostonbiotechwatch.com/wp-content/uploads/2014/10/graphs1.jpgGraphs1https://bostonbiotechwatch.com/wp-content/uploads/2014/10/folie3.jpgFolie3https://bostonbiotechwatch.com/wp-content/uploads/2014/10/folie2.jpgFolie2https://bostonbiotechwatch.com/wp-content/uploads/2014/10/folie1.jpgFigure 12014-10-16T02:51:20+00:00monthlyhttps://bostonbiotechwatch.com/2014/07/14/stealth-mode-the-new-sweet-spot-for-some-biotechs/2014-08-31T13:19:11+00:00monthlyhttps://bostonbiotechwatch.com/2014/08/13/health-it-will-europe-catch-the-wave/2014-08-14T07:05:14+00:00monthlyhttps://bostonbiotechwatch.com/2014/08/01/this-therapy-could-treat-ebola-how-to-get-it-to-those-in-need/2014-08-12T20:51:04+00:00monthlyhttps://bostonbiotechwatch.com/2014/01/23/big-data-in-drug-discovery-and-healthcare-what-is-the-tipping-point/https://bostonbiotechwatch.com/wp-content/uploads/2014/01/bd1.jpgBiotech Showcase 2014Mark Murcko, Feyi Olopade and Ajit Singh (Image courtesy EBD Group)https://bostonbiotechwatch.com/wp-content/uploads/2014/01/bd2.jpgBiotech Showcase 2014Gini Deshpande, Founder-CEO of NuMedii (Image courtesy EBD Group)https://bostonbiotechwatch.com/wp-content/uploads/2014/01/bd1-play.jpgBiotech Showcase 2014Mark Murcko, Feyi Olopade and Ajit Singh (Image courtesy EBD Group)2014-01-23T13:08:55+00:00monthlyhttps://bostonbiotechwatch.com/2014/01/21/from-a-painful-loss-a-way-to-improve-childrens-care-worldwide/https://bostonbiotechwatch.com/wp-content/uploads/2014/01/openpeds-image.jpgOPENPeds screenshotInteractive medical education: OPENPediatrics allows users to train on a “virtual ventilator” in a patient simulation.https://bostonbiotechwatch.com/wp-content/uploads/2014/01/rehma-photo.jpgRehma photoRehma passed away just days after her first birthday2014-01-30T19:43:02+00:00monthlyhttps://bostonbiotechwatch.com/2014/01/08/23andme-its-all-about-the-data/https://bostonbiotechwatch.com/wp-content/uploads/2014/01/blimp.jpg23andme BlimpGrounded?2014-01-27T02:28:49+00:00monthlyhttps://bostonbiotechwatch.com/2012/10/01/genomes-r-us-is-bgi-now-complete/https://bostonbiotechwatch.com/wp-content/uploads/2012/10/sequencing-cartoon-1-oct-12.jpgSequencing cartoon2013-11-27T16:24:50+00:00monthlyhttps://bostonbiotechwatch.com/2013/11/19/futuristic-human-on-chip-models-will-drive-better-predictions-for-efficacy-safety/https://bostonbiotechwatch.com/wp-content/uploads/2013/11/human-on-chip-of-future.jpgHuman on chip of futureThe future human-on-a-chip? Image courtesy TissUsehttps://bostonbiotechwatch.com/wp-content/uploads/2013/11/lung-on-chip.jpgLung on chipThe Wyss Institute's human breathing lung-on-a-chip mimicked pulmonary edema in humans (Image courtesy Wyss Institute http://wyss.harvard.edu/viewpressrelease/99)https://bostonbiotechwatch.com/wp-content/uploads/2013/11/moc.jpgTissUse's two-organ chipTissUse’s two-organ chip. Photo courtesy Tissuse GmbH2013-11-19T12:54:24+00:00monthlyhttps://bostonbiotechwatch.com/2013/10/07/foundations-ipo-isnt-bubbly-its-a-jolt-for-genomic-diagnostics/https://bostonbiotechwatch.com/wp-content/uploads/2013/10/champagnepop.jpgFirst day froth? First day froth? Or sustainable value creation?2013-10-24T13:13:07+00:00monthlyhttps://bostonbiotechwatch.com/2013/08/22/biotech-vcs-stung-by-startup-returns-elbow-into-royalty-financing/2013-08-22T15:20:57+00:00monthlyhttps://bostonbiotechwatch.com/2013/08/13/a-rock-star-ceo-places-an-unusual-bet-on-a-biotech/https://bostonbiotechwatch.com/wp-content/uploads/2013/08/dunsire-deborah_f_6x4-319x480.jpgDeborah Dunsire, CEO of EnVivo PharmaceuticalsPhoto courtesy Millennium: the Takeda Oncology Company2013-08-19T12:06:15+00:00monthlyhttps://bostonbiotechwatch.com/2010/03/12/genetix-pharmaceuticals-a-gene-therapy-company-takes-down-35-million-in-a-compelling-turnaround-story/https://bostonbiotechwatch.com/wp-content/uploads/2010/03/table-only.jpgTable 1: Obstacles overcome by GenetixTable 1: Obstacles overcome by Genetixhttps://bostonbiotechwatch.com/wp-content/uploads/2010/03/steven-dickman-science-280-1196-22-may-1998.jpgThe Ups and Downs of AntibodiesFigure 2: Science published this graphic in 1998 with an article of mine on the remarkable comeback of monoclonal antibodies. Now antibodies account for a large percentage of the revenues of the pharmaceutical industry. Is it the turn of gene therapy? (Graphic courtesy Science, Vol 280, Issue 5367, 1196-1197 , 22 May 1998)https://bostonbiotechwatch.com/wp-content/uploads/2010/03/genetix-legible-diagram.jpgGenetix legible diagramFigure 1: How Genetix’ gene therapy works (Graphic courtesy Genetix/CBT Advisors)https://bostonbiotechwatch.com/wp-content/uploads/2010/03/nick-leschly.jpgNick LeschlyNick Leschly, Third Rock Ventures (Image courtesy Third Rock Ventures)2013-03-23T15:55:43+00:00monthlyhttps://bostonbiotechwatch.com/2013/03/19/alternatives-to-vc-panel-video-actually-very-much-about-vc-especially-in-europe-bioeurope-spring-march-2013/2013-03-19T19:46:23+00:00monthlyhttps://bostonbiotechwatch.com/2012/12/17/moderna-therapeutics-as-the-next-genentech-not-so-fast/https://bostonbiotechwatch.com/wp-content/uploads/2012/12/central-dogma.jpgCentral Dogma2013-07-29T12:59:14+00:00monthlyhttps://bostonbiotechwatch.com/2012/03/13/can-the-amgen-takeout-of-micromet-juice-german-biotech-can-anything/https://bostonbiotechwatch.com/wp-content/uploads/2012/03/micromet-rings-the-bell-24-apr-2009.jpgMicromet rings the bell 24 Apr 2009Micromet rings the bellhttps://bostonbiotechwatch.com/wp-content/uploads/2012/03/dollar-hourglass-time-money-running-out-300x3002.jpgDollar hourglasshttps://bostonbiotechwatch.com/wp-content/uploads/2012/03/dollar-hourglass-time-money-running-out-300x3001.jpgDollar hourglass https://bostonbiotechwatch.com/wp-content/uploads/2012/03/dollar-hourglass-time-money-running-out-300x300.jpgDollar hourglass2012-03-14T09:25:20+00:00monthlyhttps://bostonbiotechwatch.com/2012/02/15/biogen-idec-lets-stromedix-do-the-hard-part/https://bostonbiotechwatch.com/wp-content/uploads/2012/02/stromedix_logo_1.jpgstromedix_logo_https://bostonbiotechwatch.com/wp-content/uploads/2012/02/stromedix_logo_.jpgstromedix_logo_2012-02-15T14:08:19+00:00monthlyhttps://bostonbiotechwatch.com/2012/01/17/quant-vc-correlation-ventures-vcs-new-dream-date/https://bostonbiotechwatch.com/wp-content/uploads/2012/01/dating-game2.jpgDating game imagehttps://bostonbiotechwatch.com/wp-content/uploads/2012/01/perfect-date.jpgPerfect dateBut will he give me deal flow in the morning?https://bostonbiotechwatch.com/wp-content/uploads/2012/01/regression-analysis1.jpgRegression analysishttps://bostonbiotechwatch.com/wp-content/uploads/2012/01/regression-analysis.jpgRegression analysishttps://bostonbiotechwatch.com/wp-content/uploads/2012/01/dating-game1.jpgDating gameDating game imagehttps://bostonbiotechwatch.com/wp-content/uploads/2012/01/dating-game.jpgDating game2012-01-17T17:29:25+00:00monthlyhttps://bostonbiotechwatch.com/2009/10/05/coming-soon-to-a-pharma-near-you-complex-tissue-culture-models/https://bostonbiotechwatch.com/wp-content/uploads/2009/10/aln-toronto.jpgALN-TorontoMicro-organoid formation out of diverse lymph node cells in agarose matrix (Image courtesy Probiogen)https://bostonbiotechwatch.com/wp-content/uploads/2009/10/micro-bioreactor-sonntag.jpgMicro bioreactor SonntagAbove, a model for the ideal multi-tissue micro-bioreactor; below, a schematic of the prototype microbioreactor of Frank Sonntag at the IWS in Dresden, which incorporates three organ growth segments, a stem cell niche cavity, three behavior sensors, three waste reservoirs and interconnecting channels. (Images courtesy Frank Sonntag)https://bostonbiotechwatch.com/wp-content/uploads/2009/10/multi-organ-image-sonntag.jpgMulti organ image Sonntaghttps://bostonbiotechwatch.com/wp-content/uploads/2009/10/nanoratchets-nature-physics-2009.jpgNanoratchets Nature Physics 2009Cells move right to left, nudged by the ratchet-like pattern of their substrate (Mahmud et al., Nature Physics 5, 606 - 612 (2009))https://bostonbiotechwatch.com/wp-content/uploads/2009/10/stratatech-3d-skin-model.jpgStratatech 3d skin modelStratatech 3-d skin model2012-01-10T14:50:33+00:00monthlyhttps://bostonbiotechwatch.com/2011/11/08/startup-targets-sweet-spot-for-consumer-health-connecting-you-with-your-data/https://bostonbiotechwatch.com/wp-content/uploads/2011/11/measured-life-tech-review-cover1.jpgMeasured life Tech Review coverhttps://bostonbiotechwatch.com/wp-content/uploads/2011/11/measured-life-tech-review-cover.jpgMeasured life Tech Review cover2013-02-27T15:55:24+00:00monthlyhttps://bostonbiotechwatch.com/2011/10/31/partnering360-a-new-social-network-aims-at-biotech-%e2%80%93-and-succeeds/2011-11-03T00:26:47+00:00monthlyhttps://bostonbiotechwatch.com/2011/09/23/big-pharma-attempts-to-extend-own-lifespan-by-activating-sirtuins/2011-09-23T12:13:38+00:00monthlyhttps://bostonbiotechwatch.com/2011/08/24/how-google-could-transform-healthcare-and-medicine/2011-08-24T12:10:47+00:00monthlyhttps://bostonbiotechwatch.com/2011/07/20/google-health-is-dead-long-live-google-plus/https://bostonbiotechwatch.com/wp-content/uploads/2011/07/sleeping-guy-rights-free.jpgSleeping GuyLooking to share data on a universal personalized health platform? Dream on!https://bostonbiotechwatch.com/wp-content/uploads/2011/07/google-health-recycled.pngGoogle Health recycledIs Google Health really going to waste, or will it be strategically recycled into a 100% post-consumer product?https://bostonbiotechwatch.com/wp-content/uploads/2011/07/sleeping-woman.jpgSleeping womanLooking to share data on a universal personalized health platform? Dream on!https://bostonbiotechwatch.com/wp-content/uploads/2011/07/withings-connected-scale.jpgWithings connected scaleComing to a Twitter feed near you2011-07-25T23:06:03+00:00monthlyhttps://bostonbiotechwatch.com/2011/04/20/exosomes-the-little-vesicles-that-could/https://bostonbiotechwatch.com/wp-content/uploads/2011/04/exosomemicrograph.jpgExosome MicrographI spy a novel class of biomarkers (Image courtesy Johan Skog, Massachusetts General Hospital)https://bostonbiotechwatch.com/wp-content/uploads/2011/04/mrdarwin.jpgCharles DarwinThere first (as usual)2012-11-13T00:13:07+00:00monthlyhttps://bostonbiotechwatch.com/2011/04/14/hacking-ourselves-%e2%80%9cbiopunk-diy-scientists-hack-the-software-of-life%e2%80%9d-by-marcus-wohlsen/https://bostonbiotechwatch.com/wp-content/uploads/2011/04/gryphon2.jpgGryphonMade to order?https://bostonbiotechwatch.com/wp-content/uploads/2011/04/young-steve-jobs-apple-inc1.gifYOUNG-STEVE-JOBS-APPLE-INCWill the next Jobs hack bio?https://bostonbiotechwatch.com/wp-content/uploads/2011/04/young-steve-jobs-apple-inc.gifYoung Steve JobsWill the next Jobs hack bio?https://bostonbiotechwatch.com/wp-content/uploads/2011/04/marcus-wohlsen.jpgMarcus WohlsenMarcus Wohlsenhttps://bostonbiotechwatch.com/wp-content/uploads/2011/04/steampunk-gear1.jpgSteampunk figureSo much DNA, so little timehttps://bostonbiotechwatch.com/wp-content/uploads/2011/04/steampunk-gear.jpgSteampunk figureSo much DNA, so little time2012-07-09T13:40:03+00:00monthlyhttps://bostonbiotechwatch.com/2011/02/07/how-sanofi-could-start-off-on-the-right-foot-in-cambridge/2011-02-07T12:42:00+00:00monthlyhttps://bostonbiotechwatch.com/2011/02/03/bugs-1-humans-0-antibiotics-the-perfect-storm-by-david-m-shlaes/https://bostonbiotechwatch.com/wp-content/uploads/2011/02/perfect-storm-cover-image.jpgAntibiotics: The Perfect Storm imagehttps://bostonbiotechwatch.com/wp-content/uploads/2011/02/david-shlaes.jpgDavid M. Shlaes2011-02-03T16:14:37+00:00monthlyhttps://bostonbiotechwatch.com/2010/04/26/vc-from-both-sides-mastering-the-vc-game-by-jeffrey-bussgang/https://bostonbiotechwatch.com/wp-content/uploads/2010/04/startup-cover.jpgStartUp coverhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/lerner-hardymon-cover.jpgLerner Venture Capital Casebook coverhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/eboys-cover.jpgeBoys coverhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/burnrate-cover.jpgBurn Rate coverhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/masteringthevc_cover1.jpgMasteringTheVC_coverhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/jeff_bussgang.jpgjeff_bussganghttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/masteringthevc_cover.jpgMastering The VC Game_cover2010-12-26T04:50:11+00:00monthlyhttps://bostonbiotechwatch.com/2010/07/01/into-the-hot-seat-%e2%80%93-scangos-to-lead-biogen-idec/https://bostonbiotechwatch.com/wp-content/uploads/2010/07/hot-seat-istock_000001596704small.jpgIn The Hot Seat2012-01-29T06:49:52+00:00monthlyhttps://bostonbiotechwatch.com/2010/12/09/lillys-big-buy-of-avid-anticipates-alzheimers-therapies-that-actually-work/https://bostonbiotechwatch.com/wp-content/uploads/2010/12/alzheimer-cells1.jpgAmyloid plaques (rat)Amyloid plaques (rat)https://bostonbiotechwatch.com/wp-content/uploads/2010/12/alzheimer-cells.jpgAmyloid plaques in ratAmyloid plaques in rat2010-12-09T14:26:52+00:00monthlyhttps://bostonbiotechwatch.com/2010/12/06/convergence-west-highlights-from-iphone-sequencing-apps-to-funding-innovation-in-biotech/https://bostonbiotechwatch.com/wp-content/uploads/2010/12/convergencelogo.pngconvergencelogo2010-12-06T23:32:15+00:00monthlyhttps://bostonbiotechwatch.com/2010/10/14/google-meets-healthcare-vc/https://bostonbiotechwatch.com/wp-content/uploads/2010/10/googled-cartoon1.jpggoogled cartoonhttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/some-questions-google.jpgsome-questions-googleBut not as many as there used to behttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/googled.jpgGoogled book jackethttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/tillman-gerngross.jpgTillman Gerngross photoTillman Gerngross, Dartmouth engineer extraordinairehttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/krishna_yeshwant.jpgKrishna YeshwantKrishna Yeshwant, photos courtesy Google web sitehttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/googled-cartoon.jpggoogled-cartoon2010-11-03T18:32:38+00:00monthlyhttps://bostonbiotechwatch.com/2010/10/04/we-are-our-bugs-hot-boston-startup-mines-the-gut/https://bostonbiotechwatch.com/wp-content/uploads/2010/10/libralogo_v_sml2.pngLibraLogo_v_sml2https://bostonbiotechwatch.com/wp-content/uploads/2010/10/zohar__1285956103_15992.jpgzohar__1285956103_1599Daphne Zohar, top Boston innovatorhttps://bostonbiotechwatch.com/wp-content/uploads/2010/10/zohar__1285956103_15991.jpgzohar__1285956103_1599https://bostonbiotechwatch.com/wp-content/uploads/2010/10/zohar__1285956103_1599.jpgzohar__1285956103_1599Daphne Zohar, top Boston innovator2010-10-05T13:26:22+00:00monthlyhttps://bostonbiotechwatch.com/2010/06/28/new-breathing-%e2%80%9clung-on-a-chip%e2%80%9d-shows-the-way-for-expanded-use-of-tissue-culture-in-preclinical-development-of-new-drugs/https://bostonbiotechwatch.com/wp-content/uploads/2010/06/ingberb2_page.jpgWyss Institute Faculty Portraits: Don IngberDon Ingber, Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University (Photo courtesy Harvard University)https://bostonbiotechwatch.com/wp-content/uploads/2010/06/lung-on-a-chip-from-science-rt_sci_jun25_huh.jpgLung on a chip from Science RT_sci_jun25_HuhSoon to feel the breath of life? Lab-created chip moves and flexes to mimic breathing (Image courtesy Science)2010-06-28T13:30:00+00:00monthlyhttps://bostonbiotechwatch.com/2010/06/14/ipo-drought-likely-to-last-boston-globe-writes/2010-06-14T04:38:49+00:00monthlyhttps://bostonbiotechwatch.com/2010/06/09/the-next-feeding-frenzy-vcs-rush-toward-diagnostics/2010-06-09T22:08:48+00:00monthlyhttps://bostonbiotechwatch.com/2010/05/25/venter-builds-a-bacterium-%e2%80%93-and-a-biotechnology-company/https://bostonbiotechwatch.com/wp-content/uploads/2010/05/moores-law-of-biology.gifMoore's Law of BiologyFigure 1: Exponential improvement in the availability of (some of) the stuff of life (Courtesy The Economist)2010-05-27T13:12:54+00:00monthlyhttps://bostonbiotechwatch.com/2010/05/27/the-boomerang-healthcare-innovation-goes-where-it-must-to-the-developing-world/https://bostonbiotechwatch.com/wp-content/uploads/2010/05/lifeimage-abetterway2.jpg'His wipeout made it to Facebook before the X-rays made it to the surgeon''His wipeout made it to Facebook before the X-rays made it to the surgeon'https://bostonbiotechwatch.com/wp-content/uploads/2010/05/lifeimage-abetterway1.jpglifeIMAGE+-+A+Better+Way"His wipeout made it to Facebook before the X-rays made it to the surgeon."https://bostonbiotechwatch.com/wp-content/uploads/2010/05/lifeimage-abetterway.jpglifeIMAGE+-+A+Better+Way"His wipeout made it to Facebook before his X-rays made it to the surgeon." (Image courtesy LifeImage)https://bostonbiotechwatch.com/wp-content/uploads/2010/05/dfa1.jpgDiagnostics for All lab-on-a-postage-stampFig. 2: Diagnostics For All paper “diagnostics lab”, offering high precision coupled with low cost and robustness required of deployment in “resource-poor settings”https://bostonbiotechwatch.com/wp-content/uploads/2010/05/mobisante-smartphone-ultrasound.jpgMobisante smartphone ultrasoundMobisante’s ultrasound smartphonehttps://bostonbiotechwatch.com/wp-content/uploads/2010/05/lifespring-hospital.jpgLifeSpring HospitalLifeSpring Hospital in Indiahttps://bostonbiotechwatch.com/wp-content/uploads/2010/05/250px-muhammad_yunus_2.jpgMuhammad YunusNobel laureate Muhammad Yunus, founder of Grameen Bankhttps://bostonbiotechwatch.com/wp-content/uploads/2010/05/clayton_christensen01.jpgClayton ChristensenClayton Christensen (photo courtesy www.claytonchristensen.com)2011-02-13T11:47:25+00:00monthlyhttps://bostonbiotechwatch.com/2010/04/08/company-serves-new-genetic-testing-market-the-not-yet-conceived/https://bostonbiotechwatch.com/wp-content/uploads/2010/04/ramji-srinivasan_95x95.jpgRamji Srinivasan, CEO of CounsylRamji Srinivasan, 28, Counsyl’s founder-CEOhttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/church.jpgGeorge Church of Harvard Medical SchoolProf. George Church, sequencing proponenthttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/murray-michael.jpgMichael Murray of Brigham & Women's HospitalMichael F. Murray: A Screen Too Far? Photo courtesy Partners Healthcare Center for Genetic and Genomic Medicinehttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/eugenic-certificate.jpgeugenic-certificateEugenics in a new light?https://bostonbiotechwatch.com/wp-content/uploads/2010/04/gattaca-movie-promo-pic.jpgGattaca Movie promo picPGD for all – except Ethan Hawkehttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/counsyl-ugt-graphic.pngCounsyl UGT graphicCounsyl claims its test will save thousands and be reimbursed by insurershttps://bostonbiotechwatch.com/wp-content/uploads/2010/04/counsyl-logo.jpgCounsyl logo2010-04-09T06:35:24+00:00monthlyhttps://bostonbiotechwatch.com/2010/02/10/domain-sheds-the-vc-blues/https://bostonbiotechwatch.com/wp-content/uploads/2010/02/wethrewanipoandnobodycame1.pngCartoon: "We Threw An IPO And Nobody Came"https://bostonbiotechwatch.com/wp-content/uploads/2010/02/riskcartoon.jpgRiskCartoonhttps://bostonbiotechwatch.com/wp-content/uploads/2010/02/somx1.pngSomaxon stock price chartFigure 2: Somaxon (NASDAQ: SOMX) suffers the wrath of the markethttps://bostonbiotechwatch.com/wp-content/uploads/2010/02/somx.pngSomaxon stock price charthttps://bostonbiotechwatch.com/wp-content/uploads/2010/02/eckard-weber-7k.jpgEckard Weber photohttps://bostonbiotechwatch.com/wp-content/uploads/2010/02/vnda.pngVanda stock price chartFigure 1: The Vanda (NASDAQ: VNDA) rollercoaster – note logarithmic scale! https://bostonbiotechwatch.com/wp-content/uploads/2010/02/wethrewanipoandnobodycame.pngCartoon: "We Threw An IPO And Nobody Came"https://bostonbiotechwatch.com/wp-content/uploads/2010/02/staticheader.jpgDomain Associates logo2010-02-10T15:28:23+00:00monthlyhttps://bostonbiotechwatch.com/2009/12/21/medicine-gets-personal-but-how-do-vcs-make-money/https://bostonbiotechwatch.com/wp-content/uploads/2009/12/raju6.jpgRaju6Raju Kucherlapati, Harvard professor and Personalized Medicine Conference founder (Image Justin A. Knight)https://bostonbiotechwatch.com/wp-content/uploads/2009/12/generationhealth-logo.jpggenerationhealth-logohttps://bostonbiotechwatch.com/wp-content/uploads/2009/12/table1.jpgAlready exitedTable 1: Diagnostics and genetic testing companies from which top-tier VCs have exitedhttps://bostonbiotechwatch.com/wp-content/uploads/2009/12/byers1.jpgBrook ByersBrook Byers, Kleiner Perkins’ diagnostics VC visionary (Image Justin A. Knight)https://bostonbiotechwatch.com/wp-content/uploads/2009/12/brook-byers.jpgBrook ByersBrook Byers, Kleiner Perkins’ diagnostics VC visionary (Image Justin A. Knight)https://bostonbiotechwatch.com/wp-content/uploads/2009/12/oncotypedx.jpgOncotypeDXhttps://bostonbiotechwatch.com/wp-content/uploads/2009/12/pill-balance.jpgPill balanceIf I take them all, will they cancel each other out?https://bostonbiotechwatch.com/wp-content/uploads/2009/12/pcpgm.gifPCPGM2010-02-05T15:26:39+00:00monthlyhttps://bostonbiotechwatch.com/2010/01/18/networking-your-medication/https://bostonbiotechwatch.com/wp-content/uploads/2010/01/proteus-digital-pill.jpgDigital pills tell allDigital pills tell all2010-05-03T23:28:36+00:00monthlyhttps://bostonbiotechwatch.com/2009/10/26/clouds-over-the-vc-sky/https://bostonbiotechwatch.com/wp-content/uploads/2009/10/peterabrooke-118x1801.gifPeterABrooke-118x180Peter Brooke, founder of TA Associates & Advent International. Advent’s global buyout fund (GPE VI) raised $10.4B in April, 2008.https://bostonbiotechwatch.com/wp-content/uploads/2009/10/peterabrooke-118x180.gifPeterABrooke-118x180Peter Brooke, founder of TA Associates & Advent International. Advent’s global buyout fund (GPE VI) raised $10.4B in April, 2008. 2010-01-15T08:00:04+00:00monthlyhttps://bostonbiotechwatch.com/2009/11/16/what-roche-is-shopping-for-%e2%80%93-and-why-it%e2%80%99s-shopping-in-israel/https://bostonbiotechwatch.com/wp-content/uploads/2009/11/rehovot.jpgRehovotIs Roche management learning Hebrew?https://bostonbiotechwatch.com/wp-content/uploads/2009/11/genentech.jpgGenentechNow that Roche owns all of Genentech, where will it get the next growth spurt?2009-11-16T17:51:36+00:00monthlyhttps://bostonbiotechwatch.com/about/2009-10-20T19:59:39+00:00weekly0.6https://bostonbiotechwatch.com/2009/10/15/17/https://bostonbiotechwatch.com/wp-content/uploads/2009/10/spiegelmer-tech.jpgSpiegelmer techFig. 1: Through the looking glass – twice. Spiegelmer precursors are synthesized against a mirror-image version of their protein target; the actual spiegelmers are mirror-reversed versions (created from L-RNA nucleotides) of the best binders (Image courtesy Medgadget.com)2009-10-16T04:15:15+00:00monthlyhttps://bostonbiotechwatch.comdaily1.02017-11-23T19:24:48+00:00